MAPK/ERK Pathway Protein Tyrosine Kinase/RTK Autophagy Apoptosis Stem Cell/Wnt JAK/STAT Signaling PI3K/Akt/mTOR Metabolic Enzyme/Protease Cytoskeleton Epigenetics Cell Cycle/DNA Damage
Raf VEGFR FLT3 Autophagy Apoptosis STAT Akt MMP Cadherin p38 MAPK ERK MEK PI3K PARP Bcl-2 Family
Sorafenib tosylate

Cat. No.: HY-10201A

Sorafenib tosylate

(Synonyms: Bay 43-9006 tosylate)

292 Cited Publications

Customer Review

Based on 292 publication(s) in Google Scholar

Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.

For research use only. We do not sell to patients.

Purity: 99.98%
CAS No.: 475207-59-1
Formula: C₂₈H₂₄ClF₃N₄O₆S
Molecular Weight:637.03

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Sorafenib tosylate Chemical Structure

CAS No.: 475207-59-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (292)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

VEGFR3

20 nM (IC₅₀)

Braf

22 nM (IC₅₀)

Raf-1

6 nM (IC₅₀)

VEGFR2

15 nM (IC₅₀)

Braf^V599E

38 nM (IC₅₀)

STAT3

MMP-2

Bcl-xL

Bcl-2

All Raf Isoforms :

All VEGFR Isoforms :

All STAT Isoforms :

All Akt Isoforms :

All MMP Isoforms :

All p38 MAPK Isoforms :

All ERK Isoforms :

All MEK Isoforms :

All PI3K Isoforms :

All PARP Isoforms :

All Bcl-2 Family Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	CC₅₀	1.17 μM Compound: SORAFENIB	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	IC₅₀	1.55 μM Compound: SORAFENIB	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1
CAKI-1	GI₅₀	3.2 μM Compound: NSC 747971	Antiproliferative activity against human CAKI-1 cells after 48 hrs by SRB assay Antiproliferative activity against human CAKI-1 cells after 48 hrs by SRB assay	[PMID: 22560627]
EKVX	GI₅₀	2.5 μM Compound: NSC 747971	Antiproliferative activity against human EKVX cells after 48 hrs by SRB assay Antiproliferative activity against human EKVX cells after 48 hrs by SRB assay	[PMID: 22560627]
HeLa	EC₅₀	>10 μM Compound: Nexavar	Toxicity in human HeLa cells assessed as cell cycle arrest at G2M phase by flow cytometry based phenotypic drug discovery based assay Toxicity in human HeLa cells assessed as cell cycle arrest at G2M phase by flow cytometry based phenotypic drug discovery based assay	[PMID: 22409666]
Hep 3B2	IC₅₀	1.5 μM Compound: 6	Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30108693]
HepG2	IC₅₀	214.8 nM Compound: ST	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
HT-29	GI₅₀	2.5 μM Compound: NSC 747971	Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 22560627]
Huh-7	IC₅₀	1.6 μM Compound: 6	Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30108693]
HUVEC	IC₅₀	1954 nM Compound: ST	Antiproliferative activity against human HUVEC assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HUVEC assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
Mahlavu	IC₅₀	0.7 μM Compound: 6	Cytotoxicity against human Mahlavu cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human Mahlavu cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30108693]
MCF7	GI₅₀	2.5 μM Compound: NSC 747971	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 22560627]
MCF7	IC₅₀	1384 nM Compound: ST	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
MDA-MB-231	IC₅₀	349.3 nM Compound: ST	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33002846]
MDA-MB-435	GI₅₀	2 μM Compound: NSC 747971	Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by SRB assay	[PMID: 22560627]
OVCAR-3	GI₅₀	3.2 μM Compound: NSC 747971	Antiproliferative activity against human OVCAR3 cells after 48 hrs by SRB assay Antiproliferative activity against human OVCAR3 cells after 48 hrs by SRB assay	[PMID: 22560627]
Sf9	IC₅₀	12.5 nM Compound: Nexavar	Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay	[PMID: 24368209]
SNB-19	GI₅₀	3.2 μM Compound: NSC 747971	Antiproliferative activity against human SNB19 cells after 48 hrs by SRB assay Antiproliferative activity against human SNB19 cells after 48 hrs by SRB assay	[PMID: 22560627]
SW-620	GI₅₀	3.2 μM Compound: NSC 747971	Antiproliferative activity against human SW620 cells after 48 hrs by SRB assay Antiproliferative activity against human SW620 cells after 48 hrs by SRB assay	[PMID: 22560627]
TK-10	GI₅₀	5 μM Compound: NSC 747971	Antiproliferative activity against human TK10 cells after 48 hrs by SRB assay Antiproliferative activity against human TK10 cells after 48 hrs by SRB assay	[PMID: 22560627]
UACC-257	GI₅₀	2 μM Compound: NSC 747971	Antiproliferative activity against human UACC257 cells after 48 hrs by SRB assay Antiproliferative activity against human UACC257 cells after 48 hrs by SRB assay	[PMID: 22560627]

In Vitro

Sorafenib (0.01-3 μM; 2 h) tosylate selectively inhibits the MAPK pathway, while has no effect on the PKB pathway in MDA-MB-231 cells^[1].
Sorafenib (0.01-15 μM; 2 h) tosylate inhibits MEK 1/2 and ERK 1/2 phosphorylation in MDA-MB-231 human breast carcinoma cells (IC₅₀s of 40 and 90 nmol/L, respectively), ERK 1/2 phosphorylation in BxPC-3, LOX, HCT 116, HT-29, Colo-205, and Mia PaCa-2 cells, but does not inhibit ERK 1/2 phosphorylation in A549 and NCI-H460 cells^[1].
Sorafenib (0.01-10 μM; 72 h) tosylate inhibits proliferation of MDA-MB-231 cells with an IC₅₀ of 2600 nmol/L)^[1].
Sorafenib (8.9 μM) tosylate exhibits an IC₅₀ of 8.9 μM in human colorectal carcinoma HCT8 and HT29 cell lines, and causes marked antagonism with oxaliplatin and cisplatin across all tested incubation schedules, reducing platinum-induced cytotoxicity^[2].
Sorafenib (4-24 μM; 24 h) tosylate reduces expression of p21^Cip1 protein and cyclin D1 expression in HCT8 and HT29 cells when incubated simultaneously with Oxaliplatin (HY-17371) or Cisplatin (HY-17394)^[2].
Sorafenib (24 μM; 4 h) tosylate significantly reduces Cisplatin- and Oxaliplatin-induced DNA adduct levels in HCT8 and HT29 cells when applied simultaneously, but does not affect adduct levels or repair when applied consecutively^[2].
Sorafenib (0-20 μmol/L; 24-72 h) tosylate inhibits the proliferation of HCCLM3, HepG2, and rat Morris hepatoma 3924A (MH) HCC cell lines in a time- and dose-dependent manner^[3].
Sorafenib (0-20 μmol/L; 2-24 h) tosylate durably inhibits phosphorylation of STAT3^Y705 and ^S727, ERK1/2, and Akt, and reduces cyclin D1 expression, without altering JAK2 or SHP2 phosphorylation, in HCCLM3, HepG2, and MH HCC cell lines^[3].
Sorafenib (5 μM; 48 h) tosylate significantly increases clonogenicity, enhances tumoursphere formation, and upregulates cancer stem cell-associated pluripotency markers Sox2 and Oct4 in A549, NCI-H460, and NCI-H1299 NSCLC cells^[5].
Sorafenib (5 μM; 48 h) tosylate increases ALDH-positive cancer stem cell populations in A549 NSCLC cells^[5].
Sorafenib (5 μM; 48 h) tosylate significantly enhances migration capacity in NCI-H460 NSCLC cells^[5].
Sorafenib (5 μM; 48 h) tosylate induces epithelial-to-mesenchymal transition in NCI-H460 NSCLC cells via downregulation of E-cadherin and upregulation of N-cadherin, vimentin, and MMP2, and activates the AKT pathway via increased AKT phosphorylation^[5].
Sorafenib (5 μM; 48 h) tosylate upregulates STMN1, FOXM1, and E2F1 expression at the mRNA and protein levels in NCI-H460 and NCI-H1299 NSCLC cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

MDA-MB-231
Concentration:

0.01-10 μM
Incubation Time:

72 h
Result:

Inhibited MDA-MB-231 cell proliferation with an IC₅₀ of 2600 nmol/L.

Western Blot Analysis^[1]

Cell Line:

MDA-MB-231
Concentration:

0.01, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time:

2 h
Result:

Dose-dependently inhibited basal MEK 1/2 phosphorylation in MDA-MB-231 cells with an IC₅₀ of 40 nmol/L.
Inhibited ERK 1/2 phosphorylation in MDA-MB-231 cells with an IC₅₀ of 90 nmol/L.
Showed no effect on PKB phosphorylation in MDA-MB-231 cells.
Completely blocked activation of the MAPK pathway.

Western Blot Analysis^[2]

Cell Line:

HCT8 and HT29 cells
Concentration:

4, 24 μM
Incubation Time:

24 h
Result:

Reduced p21Cip1 protein expression induced by Oxaliplatin or Cisplatin at 4 μM when applied simultaneously.
Completely inhibited platinum-induced p21Cip1 expression at 24 μM when applied simultaneously.
Reduced cyclin D1 expression enhanced by Oxaliplatin when applied simultaneously.
Reduced cdc2 expression enhanced by cisplatin when applied simultaneously.
Showed no effect on these protein levels when applied consecutively after platinum treatment.

Cell Proliferation Assay^[3]

Cell Line:

HCCLM3, HepG2, MH cells
Concentration:

0, 0.05, 0.1, 1, 5, 10, 20 μmol/L
Incubation Time:

24, 48, 72 h
Result:

Inhibited HCC cell growth in a time- and dose-dependent manner across all three cell lines.
Increased inhibition rates with both higher sorafenib concentrations and longer incubation periods.
Exhibited the strongest inhibition at 20 μmol/L after 72 h of treatment.

Western Blot Analysis^[3]

Cell Line:

HCCLM3, HepG2, MH cells
Concentration:

0, 2, 5, 10, 20 μmol/L
Incubation Time:

2 h (0-20 μmol/L); 2, 6, 12, 24 h (10 μmol/L)
Result:

Inhibited phosphorylation of STAT3 at Y705 and S727, as well as phosphorylation of ERK1/2, in a dose-dependent manner after 2 h of treatment across all three cell lines.
Durably inhibited phosphorylation of STAT3 (Y705 and S727) and ERK1/2 for up to 24 h at 10 μmol/L, while total STAT3 protein levels and JAK2 phosphorylation remained unchanged.
Inhibited Akt phosphorylation primarily at 2 μmol/L after 2 h and reduced cyclin D1 protein expression, while leaving SHP2 phosphorylation unchanged.

Western Blot Analysis^[5]

Cell Line:

A549, NCI-H460, NCI-H1299 cells
Concentration:

5 μM
Incubation Time:

48 h
Result:

Upregulated expression levels of Sox2 and Oct4 in all three NSCLC cell lines compared to untreated controls.
Markedly decreased the epithelial marker E-cadherin compared to untreated controls.
Correspondingly increased mesenchymal markers N-cadherin, vimentin, and MMP2 compared to untreated controls. Upregulated the expression of phosphorylated AKT in NCI-H460 cells compared to untreated controls.
Showed no obvious effect on phosphorylated JNK expression compared to untreated controls in NCI-H460 cells.
Showed an increase in phosphorylated ERK expression compared to untreated controls in NCI-H460 cells.

Cell Migration Assay ^[5]

Cell Line:

NCI-H460 cells
Concentration:

5 μM
Incubation Time:

48 h
Result:

Resulted in the strongest enhancement of cell migration.
Showed a higher CI (the capacity for cell migration) slope indicating faster migration velocity compared to DMSO-treated controls.

Western Blot Analysis^[5]

Cell Line:

NCI-H460, NCI-H1299 cells
Concentration:

5 μM
Incubation Time:

48 h
Result:

Upregulated STMN1, FOXM1, and E2F1 protein expression in both cell lines compared to untreated controls.

In Vivo

Sorafenib (7.5-60 mg/kg; p.o.; daily for 5 or 9 days) tosylate inhibits tumor growth, suppresses RAF/MEK/ERK signaling, and reduces angiogenesis in mouse breast, colon, and NSCLC xenograft models, with no observed toxicity^[1].
Sorafenib (30 mg/kg; i.g.; once daily; once daily from day 17 to day 38) tosylate inhibits hepatocellular carcinoma tumor growth and metastasis in an orthotopic rat Morris Hepatoma (MH) model, while inducing tumor apoptosis and suppressing STAT3, Akt, and ERK phosphorylation^[3].
Sorafenib (10 mg/kg; p.o.; daily; 2 weeks) tosylate exhibits antineoplastic activity in Diethyl Nitrosamin (DENA)-induced hepatocellular carcinoma in albino rats^[4].
Sorafenib (4 mg/kg; i.p.; twice a week for 4 weeks) tosylate in combined with intratumoral siTUC338 significantly reduces tumor volume in mouse HepG2/Sor xenografts via upregulation of RASAL1^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female NCr-nu/nu mice subcutaneously injected with MDA-MB-231 cells ^[1]
Dosage:

7.5; 15; 30; 60 mg/kg
Administration:

p.o.; daily for 5 or 9 days
Result:

Produced a 42% reduction in mean tumor weight after 9 days at 30 mg/kg .
Inhibited microvessel area (MVA) and microvessel density (MVD) in tumors, induced extensive tumor necrosis, reduced phosphorylated ERK 1/2 (pERK) levels, and decreased Ki-67 staining at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in treated group.

Animal Model:

Female NCr-nu/nu mice subcutaneously injected with Colo-205, HT-29, and DLD-1 cells^[1]
Dosage:

7.5; 15; 30; 60 mg/kg
Administration:

p.o.; daily for 5 or 9 days
Result:

Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days.
Reduced MVA to ~0.4% and MVD to ~80/mm² at 30 mg/kg daily for 5 days, and reduced MVA to ~0.2% and MVD to ~50/mm² at 60 mg/kg daily for 5 days relative to vehicle controls.
Detected no reduction in pERK levels at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in any treated group.
Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days.
Inhibited MVA and MVD in tumors by 50 to 80%, reduced pERK levels, and inhibited MEK 1/2 phosphorylation at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in any treated group..

Animal Model:

Female NCr-nu/nu mice subcutaneously injected with NCI-H460, and A549 cells^[1]
Dosage:

7.5; 15; 30; 60 mg/kg
Administration:

p.o.; daily; 9 days
Result:

Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily.
Caused no toxicity in any treated group.

Animal Model:

Male ACI rats (200-220 g) orthotopic implantated with Morris Hepatoma (MH) fragments^[3]
Dosage:

30 mg/kg
Administration:

i.g.; once daily from day 17 to day 38
Result:

Reduced mean tumor volume to 351.26 mm³ in early treatment group and 2248.33 mm³ in late treatment group.
Prevented lung, lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in early treatment group, and lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in late treatment group.
Induced tumor cell apoptosis with an apoptosis index of 0.909.
Reduced phosphorylation of STAT3 (Y705 and S727), Akt, and ERK in tumor tissue.
Decreased cyclin D1 expression.
Did not affect STAT3 mRNA levels, JAK2 phosphorylation, or SHP2 phosphorylation in tumor tissue.

Animal Model:

Male albino rats (100-120 g) with Diethyl Nitrosamin (DENA)-induced hepatocellular carcinoma)^[4]
Dosage:

10 mg/kg
Administration:

p.o.; daily; 2 weeks
Result:

Improved survival rate to 83.3%.
Significantly decreased liver index below normal control group level.
Reduced hepatocellular foci size by 34.8% compared to the DENA-only group.
Lowered total hepatic foci count to 10 compared to 18 in the DENA-only group.
Decreased cyclin D1 and β-catenin gene expression.
Reduced liver Bcl-2 protein and liver glutathione (GSH) levels.

Animal Model:

Male nude mice (4-6 weeks, 18-20 g) subcutaneously injected with HepG2/Sor cells^[6]
Dosage:

4 mg/kg
Administration:

i.p.; twice a week; 4 weeks
Result:

Achieved statistically significantly lower mean tumor volume compared to sorafenib combined with saline or siNC.
Significantly downregulated TUC338 expression in tumor tissue relative to control groups.
Significantly upregulated RASAL1 mRNA and protein levels in tumor tissue relative to control groups.

Chemical Information

CAS No. 475207-59-1
Appearance Solid
Molecular Weight 637.03
Formula C₂₈H₂₄ClF₃N₄O₆S
Color White to off-white
SMILES

O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
Synonyms

Bay 43-9006 tosylate
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Publications (292)

All Cell Imaging/StainingRT-PCRWBHistological Imaging/StainingIn Vivo Efficacy StudyCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma. [Abstract]

2025 Aug 1;10(1):244. PMID: 40750772
Signal Transduct Target Ther

Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study. [Abstract]

2023 Sep 14;8(1):348. PMID: 37704613
Cancer Discov

Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. [Abstract]

2021 Oct;11(10):2544-2563. PMID: 34127480
Cancer Discov

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. [Abstract]

2019 Dec;9(12):1686-1695. PMID: 31575540
Cell Metab

The thermogenic activity of adjacent adipocytes fuels the progression of ccRCC and compromises anti-tumor therapeutic efficacy. [Abstract]

2021 Oct 5;33(10):2021-2039.e8. PMID: 34508696
Nat Cancer

Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule. [Abstract]

2024 Jul;5(7):1082-1101. PMID: 38816660

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2024 Jul;5(7):1082-1101. [Abstract]

Growth inhibition, IC50 and AUC values, of OCI-AML2 cells transduced with either a non-targeting control, two PIK3CG-directed, or two PIK3R5-directed sgRNAs and treated with increasing concentrations of the FLT3 inhibitors, Gilteritinib (10-1000 nM) and Sorafenib (10-1000 nM), or KIT inhibitors, Amuvanib and Telatinib
Cancer Res

The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma. [Abstract]

2025 Aug 21. PMID: 40838989
Mol Cell

EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma. [Abstract]

2023 Dec 7;83(23):4334-4351.e7. PMID: 37979586
ACS Nano

Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation. [Abstract]

2023 Nov 28;17(22):22240-22258. PMID: 37966480

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258. [Abstract]

Western blot to detect the ferritin H protein level by the gain or loss of URB1-AS1 in sorafenib-sensitive or sorafenib-resistant HepG2 cells.

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258. [Abstract]

qPCR showing the nuclear and cytoplasmic fractions of URB1-AS1 in sorafenib-resistant HepG2 cells with β-actin and MALAT1 as cytoplasmic and nuclear controls, respectively.
Nat Commun

Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma. [Abstract]

2025 Nov 18;16(1):10096. PMID: 41253833
Nat Commun

Positive feedback between arginine methylation of YAP and methionine transporter SLC43A2 drives anticancer drug resistance. [Abstract]

2025 Jan 2;16(1):87. PMID: 39747898

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):87. [Abstract]

The cell viability of YAP-, YAP-S127A-, or YAP-R124F-overexpressed Huh-7 cells cultured in methionine-deprived medium (MD) and treated with sorafenib (1.5-3 μM) for 24 h.
Nat Commun

Synthetic vectors for activating the driving axis of ferroptosis. [Abstract]

2024 Sep 10;15(1):7923. PMID: 39256387
Nat Commun

N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis. [Abstract]

2022 Mar 18;13(1):1478. PMID: 35304469
Cell Death Differ

Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells. [Abstract]

2021 Apr;28(4):1222-1236. PMID: 33097833
Bone Res

Sorafenib inhibits ossification of the posterior longitudinal ligament by blocking LOXL2-mediated vascularization. [Abstract]

2024 Apr 10;12(1):24. PMID: 38594260

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

Sorafenib tosylate (90-900 nM) markedly suppressed the upregulation of endothelial-like differentiation in ligament cells mediated by LOXL2.

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

Sorafenib tosylate (50 mg/kg; i.g.; one daily for 14 d) significantly decreased bone volume (BV) in BMP-induced ossification mice.

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) caused sparse trabecular bone structures in BMP-induced ossification mice, accompanied by numerous cartilage structures and amorphous matrix deposition, indicating a delay in endochondral ossification.

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) significantly lowered the level of SP7 in BMP-induced ossification mice.

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d)caused a shorter response time to thermal stimulation and less paw withdrawal threshold to mechanical stimulation of BMP-induced ossification mice.
Acta Pharm Sin B

Sorafenib promotes the E3 ubiquitin ligase FBXW7 to increase tau degradation and ameliorate tauopathies. [Abstract]

2025 Nov;15(11):5817-5831. PMID: 41311387
Acta Pharm Sin B

A high-throughput Gaussia luciferase reporter assay for screening potential gasdermin E activators against pancreatic cancer. [Abstract]

2023 Oct;13(10):4253-4272. PMID: 37799380

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]

PANC-1 cells were transfected with the recombinant plasmid for 24 h and treated with sorafenib (0–70 μmol/L) for another 24 h, and then total cellular extracts were subjected to Western blotting using antibodies against caspase-3, GSDME and β-tubulin.

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]

Sorafenib (12.5-125 μM; 24 h) inhibits the viability of PANC-1 cells in a dose-dependent manner.
Acta Pharm Sin B

The suppression of cervical cancer ferroptosis by macrophages: The attenuation of ALOX15 in cancer cells by macrophages-derived exosomes. [Abstract]

2023 Jun;13(6):2645-2662. PMID: 37425043

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Jun;13(6):2645-2662. [Abstract]

HeLa and SiHa cells were treated with condition medium (CM) from human PBMC-derived M0 macrophages (Ctrl) and TAM. And then cells were treated with indicated dose of Sorafenib (Sora) for 48 h. Inhibition ratio of cell viability was detected by CCK-8 assay.
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
J Extracell Vesicles

Oxidative stress induces extracellular vesicle release by upregulation of HEXB to facilitate tumour growth in experimental hepatocellular carcinoma. [Abstract]

2024 Jul;13(7):e12468. PMID: 38944674
Autophagy

Kitasamycin overcomes ferroptosis and immunotherapy resistance by targeting the HUWE1-NCOA4-FTH1 axis. [Abstract]

2026 Feb 15:1-19. PMID: 41612599
Autophagy

The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma. [Abstract]

2022 Jan;18(1):191-203. PMID: 33960270
Adv Sci (Weinh)

Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle-Mediated Angiogenesis and the NF-κB-PCLAF Signaling Axis. [Abstract]

2025 Aug 18:e08613. PMID: 40820941
Adv Sci (Weinh)

TRIM21-Mediated K11-Linked Ubiquitination of ID1 Suppresses Tumorigenesis and Promotes Cuproptosis in Esophageal Squamous Cell Carcinoma. [Abstract]

2025 Jul 13:e02501. PMID: 40652518
Adv Sci (Weinh)

PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma. [Abstract]

2025 May 8:e2501730. PMID: 40344394
Adv Sci (Weinh)

Stabilization of TGF-β Receptor 1 by a Receptor-Associated Adaptor Dictates Feedback Activation of the TGF-β Signaling Pathway to Maintain Liver Cancer Stemness and Drug Resistance. [Abstract]

2024 Jul 9:e2402327. PMID: 38981014
Adv Sci (Weinh)

Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients. [Abstract]

2023 Sep;10(27):e2302640. PMID: 37485650
Adv Sci (Weinh)

Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression. [Abstract]

2023 Aug;10(22):e2206798. PMID: 37330650
Adv Sci (Weinh)

STING Suppresses Mitochondrial VDAC2 to Govern RCC Growth Independent of Innate Immunity. [Abstract]

2023 Jan;10(3):e2203718. PMID: 36445063
Adv Sci (Weinh)

Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy. [Abstract]

2022 May;9(15):e2105894. PMID: 35486032
Adv Sci (Weinh)

PADI2-Catalyzed MEK1 Citrullination Activates ERK1/2 and Promotes IGF2BP1-Mediated SOX2 mRNA Stability in Endometrial Cancer. [Abstract]

2021 Jan 29;8(6):2002831. PMID: 33747724
Exp Hematol Oncol

Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution. [Abstract]

2016 Jul 29:5:22. PMID: 27478685
Theranostics

Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy. [Abstract]

2020 Aug 21;10(23):10498-10512. PMID: 32929362
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
J Exp Clin Cancer Res

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. [Abstract]

2023 Jan 6;42(1):6. PMID: 36604718
J Exp Clin Cancer Res

Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma. [Abstract]

2022 Mar 30;41(1):116. PMID: 35354475
J Exp Clin Cancer Res

GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy. [Abstract]

2018 Nov 29;37(1):295. PMID: 30497501
Cell Discov

Dynamic O-GlcNAcylation coordinates ferritinophagy and mitophagy to activate ferroptosis. [Abstract]

2022 May 3;8(1):40. PMID: 35504898
Redox Biol

USP20 governs tyrosine kinase inhibitors resistance through ferroptosis evasion by targeting GPX4 in cancers. [Abstract]

2026 May:92:104086. PMID: 41844497
Redox Biol

ATF7IP inhibits Sorafenib-induced ferroptosis in hepatocellular carcinoma cells by inhibiting CYB5R2 transcription and stabilizing PARK7 protein. [Abstract]

2025 Sep:85:103786. PMID: 40716153
Redox Biol

Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors. [Abstract]

2024 Nov 5:78:103419. PMID: 39527862
Redox Biol

MAPK15 controls cellular responses to oxidative stress by regulating NRF2 activity and expression of its downstream target genes. [Abstract]

2024 Jun:72:103131. PMID: 38555711
Redox Biol

Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer. [Abstract]

2023 Feb:59:102564. PMID: 36473315
J Hazard Mater

Nanoplastic-induced NAT10/ac4C axis drives both oxidative stress and chemoresistance. [Abstract]

2025 Oct 19:499:140193. PMID: 41124733
Gut Microbes

Synergistic activity of Enterococcus Faeciu m-induced ferroptosis via expansion of IFN-γ+CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib. [Abstract]

2024 Jan-Dec;16(1):2410474. PMID: 39353096
MedComm (2020)

circRNA-SORE/UBQLN1/GPX4 Mediates the Acquisition of Sorafenib Resistance in Hepatocellular Carcinoma Through Inhibition of Ferroptosis. [Abstract]

2025 Nov 23;6(12):e70488. PMID: 41287824
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
J Immunother Cancer

Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. [Abstract]

2022 Aug;10(8):e004006. PMID: 36002188
Pharmacol Res

Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma. [Abstract]

2022 Jun;180:106244. PMID: 35550167
Pharmacol Res

Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib. [Abstract]

2022 Mar:177:106050. PMID: 34973468
Clin Cancer Res

CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma. [Abstract]

2024 Sep 13;30(18):4179-4189. PMID: 39052240
Cancer Lett

Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. [Abstract]

2022 Jan 1:524:161-171. PMID: 34687791
Cancer Lett

Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance. [Abstract]

2021 Nov 1:520:243-254. PMID: 34339801
Cancer Lett

PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling. [Abstract]

2019 May 28:450:132-143. PMID: 30849480
Int J Biol Sci

Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death. [Abstract]

2018 Apr 25;14(5):577-585. PMID: 29805309

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2018 Apr 25;14(5):577-585. [Abstract]

Hep3B, HepG2 and Huh7 cells are treated with 5 μM Sorafenib. The expressing levels of JAK1, JAK2, STAT3, SHP1, SHP2, actin and phosphorylation levels of STAT3 are determined by western blot using the antibodies, respectively.
Cell Death Dis

SOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance. [Abstract]

2026 Jan 3. PMID: 41484064
Cell Death Dis

Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models. [Abstract]

2025 Nov 17;16(1):839. PMID: 41249113
Cell Death Dis

DCAF7 recruits USP2 to facilitate hepatocellular carcinoma progression by suppressing clockophagy-induced ferroptosis. [Abstract]

2025 Aug 28;16(1):654. PMID: 40877242
Cell Death Dis

IFNγ augments TKI efficacy by alleviating protein unfolding stress to promote GSDME-mediated pyroptosis in hepatocellular carcinoma. [Abstract]

2025 Jul 11;16(1):512. PMID: 40645933
Cell Death Dis

Pharmacological targeting of the mitochondrial phosphatase PTPMT1 sensitizes hepatocellular carcinoma to ferroptosis. [Abstract]

2025 Apr 6;16(1):257. PMID: 40189563
Cell Death Dis

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment. [Abstract]

2025 Jan 26;16(1):42. PMID: 39863613
Cell Death Dis

Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma. [Abstract]

2024 Jun 5;15(6):395. PMID: 38839744
Cell Death Dis

Transcription factor Sp1 transcriptionally enhances GSDME expression for pyroptosis. [Abstract]

2024 Jan 18;15(1):66. PMID: 38238307
Adv Healthc Mater

A Novel Patient-Personalized Nanovector Based on Homotypic Recognition and Magnetic Hyperthermia for an Efficient Treatment of Glioblastoma Multiforme. [Abstract]

2023 Jul;12(19):e2203120. PMID: 37058273
Cell Death Dis

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. [Abstract]

2023 Jan 12;14(1):22. PMID: 36635256
Cell Death Dis

PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. [Abstract]

2022 Feb 4;13(2):118. PMID: 35121728
Cell Death Dis

MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. [Abstract]

2021 Jul 9;12(7):691. PMID: 34244479
Cell Death Dis

Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. [Abstract]

2019 Apr 15;10(5):331. PMID: 30988278
Genes Dis

PCK1 attenuates tumor stemness via activating the Hippo signaling pathway in hepatocellular carcinoma. [Abstract]

2023 Sep 16;11(4):101114. PMID: 38560500
Cell Commun Signal

Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis. [Abstract]

2024 Aug 7;22(1):391. PMID: 39113090
Int J Biol Macromol

KIF20A drives epithelial cell proliferation and migration in gastric adenocarcinoma, facilitating macrophage M2 polarization and subsequent immune evasion. [Abstract]

2026 Mar:351:150982. PMID: 41713545
Int J Biol Macromol

The role of solute carrier family 16 member 3 protein in hepatocellular carcinoma and sorafenib resistance. [Abstract]

2025 Oct 9;330(Pt 3):148223. PMID: 41075888
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
Phytomedicine

Usenamine a potentiates anti-CRC activity of sorafenib by inducing autophagy and inhibiting YAP pathway through targeting SOD2. [Abstract]

2026 Jun:155:158086. PMID: 41861687
Phytomedicine

Arnicolide C induces ROS-mediated modulation of PI3K/Akt and MAPK pathways to suppress MYC in hepatocellular carcinoma. [Abstract]

2025 Oct 20:148:157423. PMID: 41138574
Phytomedicine

Picropodophyllin induces ferroptosis via blockage of AKT/NRF2/SLC7A11 and AKT/NRF2/SLC40A1 axes in hepatocellular carcinoma as a natural IGF1R inhibitor. [Abstract]

2025 May 10:143:156840. PMID: 40412057
Phytomedicine

Indole-3-carbinol inhibits PD-L1-mediated immune evasion in hepatocellular carcinoma via suppressing NF-κB p105 Ubiquitination. [Abstract]

2025 Apr 1:141:156692. PMID: 40215823
Phytomedicine

Stigmasterol: Remodeling gut microbiota and suppressing tumor growth through Treg and CD8+ T cells in hepatocellular carcinoma. [Abstract]

2024 Jul:129:155225. PMID: 38678948
Phytomedicine

The role of daurisoline treatment in hepatocellular carcinoma: Inhibiting vasculogenic mimicry formation and enhancing sensitivity to sorafenib. [Abstract]

2021 Nov:92:153740. PMID: 34600176
ACS Appl Mater Interfaces

Structure-Selective Polydopamine Coating on Drug Nanoparticles. [Abstract]

2026 Jan 25. PMID: 41582522
Free Radic Biol Med

The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma. [Abstract]

2021 Feb 1;163:141-152. PMID: 33276082
Free Radic Biol Med

Ferritinophagy-mediated ferroptosis is involved in sepsis-induced cardiac injury. [Abstract]

2020 Nov 20;160:303-318. PMID: 32846217
ACS Appl Mater Interfaces

A New Spin on Antibody-Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells. [Abstract]

2017 Apr 12;9(14):12195-12202. PMID: 28319364
Drug Deliv

Andrographolide nanophytosomes exhibit enhanced cellular delivery and pro-apoptotic activities in HepG2 liver cancer cells. [Abstract]

2023 Dec;30(1):2174209. PMID: 36762548
Chemosphere

The influence of sunitinib and sorafenib, two tyrosine kinase inhibitors, on development and thyroid system in zebrafish larvae. [Abstract]

2022 Dec;308(Pt 2):136354. PMID: 36087734
Clin Sci

Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors. [Abstract]

2024 Sep 18;138(18):1131-1150. PMID: 39282930
Sens Actuators B Chem

2024 Nov 1.
Clin Sci

A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis. [Abstract]

2021 Jul 30;135(14):1751-1765. PMID: 34282832
Br J Pharmacol

DGT, a novel heterocyclic diterpenoid, effectively suppresses psoriasis via inhibition of STAT3 phosphorylation. [Abstract]

2021 Feb;178(3):636-653. PMID: 33140855
Biomed Pharmacother

Decursin induces ferroptosis via the NRF2/GPX4/SLC11A2 axis and suppresses migration in hepatocellular carcinoma. [Abstract]

2026 Feb:195:118941. PMID: 41496356
Biomed Pharmacother

Inhibition of the PI3K/AKT signaling pathway contributes to the anti-renal cell carcinoma effects of deoxyelephantopin. [Abstract]

2025 May 8:187:118136. PMID: 40344699
J Transl Med

Endogenous protein S100A14 stabilizes glutaminase to render hepatocellular carcinoma resistant to sorafenib. [Abstract]

2025 Apr 11;23(1):435. PMID: 40217256
J Transl Med

RPL22L1 fosters malignant features of cervical cancer via the modulation of DUSP6-ERK axis. [Abstract]

2025 Feb 28;23(1):244. PMID: 40022129
J Transl Med

Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma. [Abstract]

2024 Aug 28;22(1):792. PMID: 39198815
J Transl Med

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. [Abstract]

2023 Jan 9;21(1):9. PMID: 36624452
Biomed Pharmacother

Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma. [Abstract]

2022 Sep:153:113540. PMID: 36076618
J Transl Med

RAF1 promotes lymphatic metastasis of hypopharyngeal carcinoma via regulating LAGE1: an experimental research. [Abstract]

2022 Jun 6;20(1):255. PMID: 35668458
Biomed Pharmacother

TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib. [Abstract]

2020 Jun;126:109862. PMID: 32120157
Biomed Pharmacother

Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients. [Abstract]

2017 Feb:86:27-31. PMID: 27936391
Cell Mol Gastroenterol Hepatol

Sorafenib Promotes Treg Cell Differentiation To Compromise Its Efficacy via VEGFR/AKT/Foxo1 Signaling in Hepatocellular Carcinoma. [Abstract]

2024 Dec 30:101454. PMID: 39743020
Oncogene

LINC-AC092535.5 regulates MICAL2 mRNA level to inhibit p53-mediated ferroptosis in nasopharyngeal carcinoma. [Abstract]

2026 Apr;45(14):1260-1274. PMID: 41832266
Stem Cell Res Ther

Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy. [Abstract]

2023 Apr 1;14(1):58. PMID: 37005657
Oncogene

PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells. [Abstract]

2022 Mar;41(13):1851-1865. PMID: 35140333
Oncogene

Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. [Abstract]

2021 Aug;40(34):5302-5313. PMID: 34247189
Cell Death Discov

Engineered small extracellular vesicles loaded with miR-654-5p promote ferroptosis by targeting HSPB1 to alleviate sorafenib resistance in hepatocellular carcinoma. [Abstract]

2023 Sep 30;9(1):362. PMID: 37777559
Cell Death Discov

Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma. [Abstract]

2022 Aug 17;8(1):365. PMID: 35973992
Cell Rep

A shear stress-responsive pathway in monocytes drives cardiopulmonary bypass-induced inflammation via spectrin/RAF1/store-operated calcium entry. [Abstract]

2026 Jan 22;45(2):116903. PMID: 41579376
Cell Rep

Carbonic anhydrase 2 facilitates sorafenib resistance by counteracting MCT4-mediated intracellular pH dysregulation in HCC. [Abstract]

2024 Nov 27;43(12):114996. PMID: 39607826
Cell Rep

STUB1-mediated ubiquitination and degradation of NSUN2 promotes hepatocyte ferroptosis by decreasing m5C methylation of Gpx4 mRNA. [Abstract]

2024 Oct 24;43(11):114885. PMID: 39453812
Cell Rep

Intratumor Mycoplasma promotes the initiation and progression of hepatocellular carcinoma. [Abstract]

2023 Dec 12;42(12):113563. PMID: 38088929
Clin Transl Med

Oncofetal dual‑specificity phosphatase 9 drives stem-like properties through ERK1/2-PPARG-SCD axis-mediated lipid metabolism in hepatocellular carcinoma. [Abstract]

2025 Dec;15(12):e70550. PMID: 41383134
Clin Transl Med

USP22 promotes the proliferation and Sorafenib resistance of hepatocellular carcinoma cells via its deubiquitinase activity. [Abstract]

2025 May;15(5):e70324. PMID: 40341781
J Med Chem

Discovery of Highly Potent AKR1C3 Inhibitors Treating Sorafenib-Resistant Hepatocellular Carcinoma. [Abstract]

2025 Mar 27. PMID: 40143712
Clin Transl Med

Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation. [Abstract]

2023 Jun;13(6):e1300. PMID: 37337470
J Med Chem

Protein Stability Effects in Aggregate-Based Enzyme Inhibition. [Abstract]

2019 Nov 14;62(21):9593-9599. PMID: 31589047
Br J Cancer

Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. [Abstract]

2017 Sep 26;117(7):974-983. PMID: 28850563

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Br J Cancer. 2017 Sep 26;117(7):974-983. [Abstract]

The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor-AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.
Int J Nanomedicine

A Novel Triptolide Nano-Liposome with Mitochondrial Targeting for Treatment of Hepatocellular Carcinoma. [Abstract]

2024 Dec 3:19:12975-12998. PMID: 39654802
Comput Biol Med

Liquid-liquid phase separation-related lncRNA prognostic signature and ZNF32-AS2 as a novel biomarker in hepatocellular carcinoma. [Abstract]

2024 Feb:169:107975. PMID: 38199212
Cancer Cell Int

Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]

2025 Oct 15;25(1):357. PMID: 41094661
Biomater Adv

Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. [Abstract]

2022 May:136:212761. PMID: 35929305
Cancer Cell Int

The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein. [Abstract]

2019 Aug 27;19:222. PMID: 31467488
Cell Biol Toxicol

Protocatechuic acid relieves ferroptosis in hepatic lipotoxicity and steatosis via regulating NRF2 signaling pathway. [Abstract]

2024 Nov 26;40(1):104. PMID: 39589556
Eur J Med Chem

Novel inhibitors targeting the PGK1 metabolic enzyme in glycolysis exhibit effective antitumor activity against kidney renal clear cell carcinoma in vitro and in vivo. [Abstract]

2024 Mar 5:267:116209. PMID: 38354523
Cell Biol Toxicol

The mtDNA-STING pathway plays an important role in both navitoclax- and S63845-induced autophagy and enhances cell death. [Abstract]

2023 Dec;39(6):2821-2839. PMID: 37002446
Int J Mol Med

STOML2 interacts with PHB to activate the MEK/ERK signaling pathway and mediates autophagy‑related proteins in the progression of hepatocellular carcinoma. [Abstract]

2026 Feb;57(2):38. PMID: 41347828
Chin Med

Polyphyllin I exerts anti-hepatocellular carcinoma activity by targeting ZBTB16 to activate the PPARγ/RXRα signaling pathway. [Abstract]

2024 Aug 24;19(1):113. PMID: 39182119
Biochem Pharmacol

Low Pi stress enhances the sensitivity of hepatocellular carcinoma to sorafenib. [Abstract]

2023 Jul:213:115593. PMID: 37196682
Biochem Pharmacol

ALOX5 Promotes Autophagy-dependent Ferroptosis by Activating the AMPK/mTOR Pathway in Melanoma. [Abstract]

2023 Jun:212:115554. PMID: 37080437
Biochem Pharmacol

Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. [Abstract]

2019 Nov:169:113612. PMID: 31437461
Mol Cancer Ther

Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma. [Abstract]

2020 May;19(5):1197-1209. PMID: 32220970
Lab Chip

A novel microfluidic self-perfusion chip (MSPC) for pumpless 3D cell, microtissue and organoid culture. [Abstract]

2025 Apr 10. PMID: 40206017
World J Gastroenterol

Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma. [Abstract]

2021 Jul 28;27(28):4667-4686. PMID: 34366628
J Ethnopharmacol

Modulation of the VEGF/AKT/eNOS signaling pathway to regulate liver angiogenesis to explore the anti-hepatic fibrosis mechanism of curcumol. [Abstract]

2021 Nov 15:280:114480. PMID: 34358654
J Enzyme Inhib Med Chem

Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions. [Abstract]

2020 Dec;35(1):344-353. PMID: 31851852
Lab Chip

Development of a biomimetic liver tumor-on-a-chip model based on decellularized liver matrix for toxicity testing. [Abstract]

2018 Nov 6;18(22):3379-3392. PMID: 30298144
Cancer Immunol Immunother

Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma. [Abstract]

2026 Apr 10;75(5):140. PMID: 41961075
Commun Biol

Isoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism. [Abstract]

2025 Feb 8;8(1):205. PMID: 39922943
Commun Biol

USP24 promotes autophagy-dependent ferroptosis in hepatocellular carcinoma by reducing the K48-linked ubiquitination of Beclin1. [Abstract]

2024 Oct 8;7(1):1279. PMID: 39379617
Drug Des Devel Ther

Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation. [Abstract]

2024 Sep 12:18:4065-4088. PMID: 39286286
Int J Mol Sci

XON9-A Glyco-Humanized Polyclonal Antibody Effective Against Hepatocellular Carcinoma. [Abstract]

2025 Sep 20;26(18):9185. PMID: 41009747
Biol Direct

L-741626 inhibits hepatocellular carcinoma progression by targeting Ref-1 to suppress MAPK/ERK signalling pathway activity. [Abstract]

2025 Apr 16;20(1):54. PMID: 40241114
Biol Direct

Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinoma. [Abstract]

2024 Nov 11;19(1):110. PMID: 39529192
Int J Mol Sci

The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer. [Abstract]

2023 Dec 23;25(1):269. PMID: 38203437
Int J Mol Sci

SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma. [Abstract]

2022 Sep 21;23(19):11092. PMID: 36232407
Chin J Nat Med

Two cardenolide glycosides from the seed fairs of Asclepias curassavica and their cytotoxic activities. [Abstract]

2022 Mar;20(3):202-209. PMID: 35369964
Front Pharmacol

Protein and metabolic profiles of tyrosine kinase inhibitors co-resistant liver cancer cells. [Abstract]

2024 May 21:15:1394241. PMID: 38835670
Front Pharmacol

Caryophyllene Oxide Induces Ferritinophagy by Regulating the NCOA4/FTH1/LC3 Pathway in Hepatocellular Carcinoma. [Abstract]

2022 Jul 11;13:930958. PMID: 35899120
Eur J Pharmacol

Neoprzewaquinone A suppresses hepatocellular carcinoma through promoting the ubiquitin-related degradation of EGFR and inhibiting PI3K-AKT pathway. [Abstract]

2025 Oct 21:1007:178274. PMID: 41130376
Bioorg Chem

Synthesis and evaluation of sulfonamide-chalcone hybrid compounds as inhibitors of VEGFR1/VEGFR2-mediated angiogenesis. [Abstract]

2025 Aug 21:164:108903. PMID: 40848708
Int Immunopharmacol

ASIC1a regulates ferroptosis in hepatic stellate cells via the Hippo/Yap-1 pathway in liver fibrosis. [Abstract]

2024 Sep 30;143(Pt 1):113226. PMID: 39353388
Eur J Pharmacol

Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy. [Abstract]

2021 Sep 5:906:174217. PMID: 34087223
Toxicology

Sorafenib induces intestinal toxicity by disturbing gut microbiota and activating the LPS/TLR4/NF-κB signaling pathway in mice. [Abstract]

2025 Jun 13:517:154220. PMID: 40518001
RSC Adv

Self-assembled nanoplatform-mediated co-delivery of brusatol to sensitize sorafenib for hepatocellular carcinoma treatment. [Abstract]

2025 Apr 14;15(15):11675-11687. PMID: 40230634
Hepatol Commun

Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway. [Abstract]

2024 Mar 29;8(4):e0405. PMID: 38573832
Toxicology

Inhibitory effects of flavonoids on glucose transporter 1 (GLUT1): From library screening to biological evaluation to structure-activity relationship. [Abstract]

2023 Apr:488:153475. PMID: 36870413
Neuropharmacology

Sorafenib promotes sensory conduction function recovery via miR-142-3p/AC9/cAMP axis post dorsal column injury. [Abstract]

2019 Apr:148:347-357. PMID: 30710569
Molecules

Facilitating Anti-Cancer Combinatorial Drug Discovery by Targeting Epistatic Disease Genes. [Abstract]

2018 Mar 23;23(4). pii: E736. PMID: 29570606
RSC Adv

2018 8:6425-6435.
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Mol Oncol

Loss of GABARAPL1 confers ferroptosis resistance to cancer stem-like cells in hepatocellular carcinoma. [Abstract]

2022 Oct;16(20):3703-3719. PMID: 36062307
Clin Epigenetics

Decitabine regulates the resistance of HCC to sorafenib through demethylation. [Abstract]

2025 Jul 7;17(1):120. PMID: 40624511
Cancers (Basel)

Sorafenib Resistance Contributed by IL7 and MAL2 in Hepatocellular Carcinoma Can Be Overcome by Autophagy-Inducing Stapled Peptides. [Abstract]

2023 Nov 3;15(21):5280. PMID: 37958451
Cancers

CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling. [Abstract]

2020 Jun 30;12(7):1737. PMID: 32629802
ACS Omega

Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]

2025 Oct 29;10(44):52562-52575. PMID: 41244417
FASEB J

Blocking the ADAM9/ITGAV Pathway Ameliorates Sepsis-Induced Acute Lung Injury by Promoting Macrophage Efferocytosis. [Abstract]

2025 Aug 15;39(15):e70845. PMID: 40736047
J Clin Transl Hepatol

HBx Facilitates Drug Resistance in Hepatocellular Carcinoma via CD133-regulated Self-renewal of Liver Cancer Stem Cells. [Abstract]

2025 Jan 28;13(1):15-24. PMID: 39801781
J Mol Med (Berl)

c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway. [Abstract]

2022 Apr;100(4):585-598. PMID: 35122106
iScience

Phospho-JNK agonists show promising effects for the treatment of hepatocellular carcinoma. [Abstract]

2026 May 20;29(6):116005. PMID: 42211113
Oncol Res

Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway. [Abstract]

2025 May 29;33(6):1459-1472. PMID: 40486881
Transl Oncol

Targeting STK26 and ATG4B: miR-22-3p as a modulator of autophagy and tumor progression in HCC. [Abstract]

2024 Nov 27:51:102214. PMID: 39608212
iScience

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. [Abstract]

2023 May 29;26(7):106994. PMID: 37534166
Virol Sin

Identification of a receptor tyrosine kinase inhibitor CP-724714 inhibits SADS-CoV related swine diarrhea coronaviruses infection in vitro. [Abstract]

2023 Oct;38(5):778-786. PMID: 37406816
Sci Rep

Chemotherapy-derived DAMPs drive reprogramming of tumor-associated macrophages toward a pro-inflammatory phenotype in hepatocellular carcinoma. [Abstract]

2026 Apr 3;16(1):17440. PMID: 41933190
J Biotechnol

FRET two-hybrid assay-based target drug screening in living cells. [Abstract]

2025 Nov 12:410:1-9. PMID: 41238124
Sci Rep

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma. [Abstract]

2025 Oct 15;15(1):36061. PMID: 41093994
Sci Rep

Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis. [Abstract]

2025 Aug 7;15(1):28871. PMID: 40775250
Sci Rep

Dimethyl fumarate abrogates hepatocellular carcinoma growth by inhibiting Nrf2/Bcl-xL axis and enhances sorafenib's efficacy. [Abstract]

2025 May 14;15(1):16724. PMID: 40369009
Sci Rep

Novel use of FDA-approved drugs identified by cluster analysis of behavioral profiles. [Abstract]

2022 Apr 21;12(1):6120. PMID: 35449173
Oncol Rep

EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer. [Abstract]

2021 Feb;45(2):776-785. PMID: 33416143
Oncol Rep

Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib. [Abstract]

2018 Sep;40(3):1525-1532. PMID: 30015938

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Sep;40(3):1525-1532. [Abstract]

SMMC-7721 and HepG2 cells are treated with 4 µM Sorafenib and 100 µM Berberine alone or in combination (4 µM Sorafenib+100 µM Berberine) for 72 h, and the expression levels of apoptosis-associated proteins are measured by western blot analysis.
Sci Rep

Glycosylation-dependent galectin-1/neuropilin-1 interactions promote liver fibrosis through activation of TGF-β- and PDGF-like signals in hepatic stellate cells. [Abstract]

2017 Sep 8;7(1):11006. PMID: 28887481
Oncol Rep

Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. [Abstract]

2017 Jan;37(1):273-280. PMID: 27878301
Dig Liver Dis

Tumor suppressor CLCA1 inhibits angiogenesis via TGFB1/SMAD/VEGF cascade and sensitizes hepatocellular carcinoma cells to Sorafenib. [Abstract]

2024 Jan;56(1):176-186. PMID: 37230858
J Pharmacol Exp Ther

Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis. [Abstract]

2017 Aug;362(2):219-229. PMID: 28515157

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. [Abstract]

The combination of sorafenib and CAI induces apoptosis in NSCLC. Effect of 10 μM CAI and/or 5 μM Sorafenib on the expression of cleaved PARP and cleaved caspase-. Protein levels of cleaved PARP and cleaved caspase-3 from treated cell lysates are normalized against GAPDH levels.
ACS Chem Biol

Internal Structure and Preferential Protein Binding of Colloidal Aggregates. [Abstract]

2017 Jan 20;12(1):282-290. PMID: 27983786
ACS Chem Biol

Stable Colloidal Drug Aggregates Catch and Release Active Enzymes. [Abstract]

2016 Apr 15;11(4):992-1000. PMID: 26741163
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
Cell Signal

Natural exosome-like nanovesicles from Salvia chinensis Benth induce ferroptosis to suppress hepatocellular carcinoma progression via AMPK/Nrf2/xCT axis. [Abstract]

2025 Jun 6:111928. PMID: 40484104
Cell Signal

Sorafenib inhibits multiple sclerosis by regulating T cell differentiation. [Abstract]

2025 Sep:133:111872. PMID: 40389044
Biochim Biophys Acta Mol Cell Res

Salinomycin inhibits SREBP1 to sensitize ferroptosis and ameliorate sorafenib resistance in clear cell renal cell carcinoma. [Abstract]

2025 May 11:119989. PMID: 40360020
PLoS Genet

TRIM21 modulates stability of pro-survival non-coding RNA vtRNA1-1 in human hepatocellular carcinoma cells. [Abstract]

2025 Mar 17;21(3):e1011614. PMID: 40096176
Cell Signal

Nuclear export of PML promotes p53-mediated apoptosis and ferroptosis. [Abstract]

2024 Jun 27:111278. PMID: 38944257
Heliyon

Naringenin enhances the efficacy of ferroptosis inducers by attenuating aerobic glycolysis by activating the AMPK-PGC1α signalling axis in liver cancer. [Abstract]

2024 May 31;10(11):e32288. PMID: 38912485
Heliyon

Paeoniflorin increases the anti-tumor efficacy of sorafenib in tumor-bearing mice with liver cancer via suppressing the NF-κb/PD-l1 axis. [Abstract]

2024 Jan 13;10(2):e24461. PMID: 38312647
Biology (Basel)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2. [Abstract]

2023 Oct 16;12(10):1337. PMID: 37887047
Med Oncol

The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death. [Abstract]

2022 Sep 29;39(12):221. PMID: 36175804
Exp Cell Res

12 T high static magnetic field suppresses osteosarcoma cells proliferation by regulating intracellular ROS and iron status. [Abstract]

2022 Aug 15;417(2):113223. PMID: 35643180
Exp Cell Res

Dichloroacetate enhances the anti-tumor effect of sorafenib via modulating the ROS-JNK-Mcl-1 pathway in liver cancer cells. [Abstract]

2021 Sep 1;406(1):112755. PMID: 34332981
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
NPJ Syst Biol Appl

Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma. [Abstract]

2019 Aug 16:5:29. PMID: 31452933
Eur J Med Res

Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]

2025 Aug 4;30(1):704. PMID: 40760677
BMC Complement Med Ther

Therapeutic efficacy of sorafenib and plant-derived phytochemicals in human colorectal cancer cells. [Abstract]

2023 Jun 26;23(1):210. PMID: 37365571
Saudi Pharm J

Development and validation of a UPLC-MS/MS method for simultaneous detection of doxorubicin and sorafenib in plasma: Application to pharmacokinetic studies in rats. [Abstract]

2023 Jul;31(7):1317-1326. PMID: 37323919
J Hepatocell Carcinoma

Inhibitory Effects of Esculetin on Liver Cancer Through Triggering NCOA4 Pathway-Mediation Ferritinophagy in vivo and in vitro. [Abstract]

2023 Apr 11:10:611-629. PMID: 37069958
Phytochemistry

Five undescribed steroids from Talaromyces stipitatus and their cytotoxic activities against hepatoma cell lines. [Abstract]

2021 Sep:189:112816. PMID: 34087503
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
BMC Cancer

Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. [Abstract]

2019 Aug 1;19(1):760. PMID: 31370822
Endocrinology

TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice. [Abstract]

2023 Aug 28;164(10):bqad135. PMID: 37702560
Front Oncol

Silenced LINC01134 Enhances Oxaliplatin Sensitivity by Facilitating Ferroptosis Through GPX4 in Hepatocarcinoma. [Abstract]

2022 Jul 8;12:939605. PMID: 35875091
Front Oncol

Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. [Abstract]

2021 Jul 13:11:704042. PMID: 34327143
J Cancer

SREBP1-SCD1 enhanced MUFAs Biosynthesis drives Nutrient Deprived Pancreatic cancer cell Ferroptosis Resistance. [Abstract]

2025 Sep 8;16(13):3960-3971. PMID: 41049011
NAR Cancer

Regulation of angiogenesis and cancer cell proliferation by human vault RNA1-2. [Abstract]

2025 Aug 30;7(3):zcaf028. PMID: 40918645
Mol Carcinog

CYP4F11, an NRF2 Target Gene, Promotes Hepatocellular Carcinoma Cell Growth. [Abstract]

2025 Jul;64(7):1264-1274. PMID: 40329467
Mol Carcinog

Transmembrane protein 147, as a potential Sorafenib target, could expedite cell cycle process and confer adverse prognosis in hepatocellular carcinoma. [Abstract]

2023 Sep;62(9):1295-1311. PMID: 37212496
Environ Toxicol

Tanshinone IIA inhibits gastric cancer cell stemness through inducing ferroptosis. [Abstract]

2022 Feb;37(2):192-200. PMID: 34661962
J Cancer

The Inhibitory Effects of Recombinant Hespintor Combined with Sorafenib on Transplanted Human Hepatoma in Nude Mice, and Transcriptional Regulation of Hespintor Based on RNA-Seq. [Abstract]

2021 Jan 1;12(2):343-357. PMID: 33391431
Int J Med Sci

LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. [Abstract]

2021 Jan 29;18(6):1456-1464. PMID: 33628103
Am J Hypertens

Mineralocorticoid Receptor in Endothelial Cells Contributes to Vascular Endothelial Growth Factor Receptor Inhibitor-Induced Vascular and Kidney Damage. [Abstract]

2025 Jan 16;38(2):104-110. PMID: 39514632
Front Biosci (Landmark Ed)

Downregulation of MTHFD2 Inhibits Proliferation and Enhances Chemosensitivity in Hepatocellular Carcinoma via PI3K/AKT Pathway. [Abstract]

2024 Jan 19;29(1):35. PMID: 38287824
Kaohsiung J Med Sci

Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression. [Abstract]

2022 Feb;38(2):157-164. PMID: 35142429
Mol Immunol

Sophora tonkinensis reprograms tumor-associated macrophages to M1-like phenotype and exerts anti-hepatocellular carcinoma effects. [Abstract]

2026 Mar:191:49-59. PMID: 41666700
Curr Issues Mol Biol

Exploring the Molecular Mechanism of 1,25(OH)2D3 Reversal of Sorafenib Resistance in Hepatocellular Carcinoma Based on Network Pharmacology and Experimental Validation. [Abstract]

2025 Apr 29;47(5):319. PMID: 40699718
Diseases

Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics. [Abstract]

2023 Oct 23;11(4):147. PMID: 37873791
Mol Cell Probes

Circular RNA ITCH increases sorafenib-sensitivity in hepatocellular carcinoma via sequestering miR-20b-5p and modulating the downstream PTEN-PI3K/Akt pathway. [Abstract]

2023 Feb:67:101877. PMID: 36442661
Discov Oncol

Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma. [Abstract]

2023 May 27;14(1):83. PMID: 37243813

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]

Sorafenib (0.25, 0.5, 1, 2, 4, 6 µM; 24 h) significantly inhibits the cell viability of HepG2 and Hep3B.

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]

Sorafenib (3 µM; 24 h) significantly inhibits the cell proliferation of HepG2 and Hep3B.
Am J Cancer Res

Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt. [Abstract]

2017 Dec 1;7(12):2503-2514. PMID: 29312803

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. [Abstract]

VPA potentiates anti-tumor effects of Sorafenib tosylate in vivo. The expression of cleaved caspase9, cleaved caspase3, cleaved PARP from tumor tissue homogenates are analyzed by western blot.
J Chromatogr B Analyt Technol Biomed Life Sci

Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. [Abstract]

2024 Apr 15:1237:124100. PMID: 38547701
Int J Biochem Cell Biol

Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells. [Abstract]

2020 Sep;126:105820. PMID: 32750425
J Chromatogr B Analyt Technol Biomed Life Sci

Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method. [Abstract]

2017 Sep 1:1061-1062:220-224. PMID: 28750235
Toxicol Mech Methods

A novel in vitro assay for rapid screening of embryotoxicity in multiple species. [Abstract]

2025 Sep 10:1-8. PMID: 40908820
Toxicol In Vitro

Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK. [Abstract]

2021 Oct:76:105226. PMID: 34293431
PLoS One

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]

2024 Nov 1;19(11):e0308647. PMID: 39485774
Clin Transl Oncol

FAT4 loss promotes tumor growth and ferroptosis resistance in hepatocellular carcinoma via PI3K/AKT pathway activation. [Abstract]

2026 Mar 14. PMID: 41832339
Fundam Clin Pharmacol

Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma. [Abstract]

2021 Aug;35(4):690-699. PMID: 33015852
Prostate

MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components. [Abstract]

2018 Apr;78(5):343-352. PMID: 29341215
Can J Gastroenterol Hepatol

Hsa_circ_0006988 Promotes Sorafenib Resistance of Hepatocellular Carcinoma by Modulating IGF1 Using miR-15a-5p. [Abstract]

2022 Dec 24:2022:1206134. PMID: 36594050
Biomed Res Int

A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction. [Abstract]

2019 Nov 28;2019:2410845. PMID: 31871933
Biochem Biophys Res Commun

Natural exosome-like nanovesicles from Smilax China rhizome induce mitophagy-dependent ferroptosis in hepatocellular carcinoma via GPX4/ACSL4 axis. [Abstract]

2026 Feb 12:800:153270. PMID: 41529459
BMJ Open Ophthalmol

Impact of anticancer drugs on human Tenon's fibroblast proliferation: implications for glaucoma surgery. [Abstract]

2026 Jan 12;11(1):e002307. PMID: 41526033
Biochem Biophys Res Commun

Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers. [Abstract]

2023 Sep 3:671:335-342. PMID: 37327705
Biochem Biophys Res Commun

The deubiquitinating enzyme USP20 regulates the stability of the MCL1 protein. [Abstract]

2022 Feb 19:593:122-128. PMID: 35063767
Biochem Bioph Res Co

Functional loss of TAGLN inhibits tumor growth and increases chemosensitivity of non-small cell lung cancer. [Abstract]

2020 Sep 3;529(4):1086-1093. PMID: 32819569
Liver Res

2025 Sep 22.
Endocr J

Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells. [Abstract]

2017 Nov 29;64(11):1115-1123. PMID: 28855436

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]

Effect of Sorafenib on phosphorylation of ERK and AKT. Thyroid cancer cells are treated for 30 minutes with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The levels of ERK and AKT phosphorylation are examined by immunoblot analysis. β-actin is used as the control. Sorafenib suppresses phosphorylation of ERK, but not of AKT.

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]

Effect of Sorafenib and Forskolin on expression of CDK4 and CDK regulatory proteins. Thyroid cancer cells are treated for 24 hours with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The expression of cyclin D1, CDK4, and phosphorylation of RB are examined by immunoblot analysis. β-actin is used as the control. The combination therapy suppresses expression of cyclin D1, and Forskolin monotherapy suppresses expression of cyclin D1 in TPC-1 and W
Int J Environ Health Res

Investigation of synergistic effects of silver nanoparticles with sorafenib on in vitro prostate and head and neck cancer models. [Abstract]

2025 Apr 24:1-9. PMID: 40270101
Clin Med Insights Oncol

Exploring the Clinical Implications of RPL3 Presence in BRCA-Associated Cancers: Unraveling the Interplay With Cancer Immunity. [Abstract]

2024 Oct 16:18:11795549241285387. PMID: 39429685
Ann Med Surg (Lond)

Synergistic mechanism of Shengyang Shiyiwei Pill in enhancing bevacizumab efficacy for hepatocellular carcinoma-associated ascites. [Abstract]

2025 Nov 25;88(1):290-302. PMID: 41496997
Scand J Immunol

IL-6 upregulates the expression of IL-6R through the JAK2/STAT3 signalling pathway to promote progression of hepatocellular carcinoma. [Abstract]

2023 Jul;98(1):e13271. PMID: 38441314
Am J Transl Res

ETS-1/c-Met drives resistance to sorafenib in hepatocellular carcinoma. [Abstract]

2023 Feb 15;15(2):896-913. PMID: 36915773
Am J Transl Res

Phenformin synergistically sensitizes liver cancer cells to sorafenib by downregulating CRAF/ERK and PI3K/AKT/mTOR pathways. [Abstract]

2021 Jul 15;13(7):7508-7523. PMID: 34377232
Am J Transl Res

CXCR3 confers sorafenib resistance of HCC cells through regulating metabolic alteration and AMPK pathway. [Abstract]

2020 Mar 15;12(3):825-836. PMID: 32269715
Braz J Med Biol Res

MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling. [Abstract]

2021 May 31;54(9):e10390. PMID: 34076140
Integr Biol (Camb)

Structural insights and influence of V599 mutations on the overall dynamics of BRAF protein against its kinase domains. [Abstract]

2018 Oct 15;10(10):646-657. PMID: 30229251
Int J Clin Exp Pathol

2017;10(3):3033-3042.
Int J Clin Exp Pathol

SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway. [Abstract]

2015 Apr 1;8(4):3871-81. PMID: 26097571

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).
bioRxiv

2026 Jun 11.
chemRxiv

2026 May 17.
bioRxiv

2026 May 19.
bioRxiv

2026 Apr 16.
bioRxiv

2026 Apr 24.
chemRxiv

2026 Apr 6.
bioRxiv

2026 Mar 31.
Res Sq

2026 Mar 18.
bioRxiv

2025 Oct 15.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
Res Sq

2025 Jul 13.
Res Sq

2024 Sep 16.
SSRN

2024 Oct 16.
Research Square Preprint

2023 Nov 11.
SSRN

2023 Apr 24.
Research Square Preprint

2023 Mar 29.
Research Square Print

2023 Feb 20.
SSRN

2023 Jan 27.
Research Square Print

October 3rd, 2022.
Evid Based Complement Alternat Med

Effects of Sensitized Sorafenib with a Paeoniflorin and Geniposide Mixture on Liver Cancer via the NF- κ B-HIF-2 α-SerpinB3 Pathway. [Abstract]

2022 Oct 15:2022:1911311. PMID: 36285158
Patent

US20220305013A1.
Research Square Preprint

2022 Jul.
Research Square Preprint

2022 May.
Research Square Preprint

2022 Jan.
Journal of Pharmaceutical Research International

33(47B): 274-279, 2021.
Research Square Preprint

2021 Aug.
Advances in Parkinsons Disease

2021, 10, 1-13.
Pak J Zool

2021 May.
bioRxiv

2021 Jan 25.
University of Toronto

2019 Aug.
Math Biosci Eng

Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma. [Abstract]

2019 Jul 8;16(6):6319-6334. PMID: 31698564
Personalized Medicine Universe

2019 May.
Patent

US20180263995A1.
Oncotarget

Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. [Abstract]

2017 Oct 6;8(52):90185-90196. PMID: 29163820
Oncotarget

Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. [Abstract]

2017 May 2;8(18):29771-29784. PMID: 28404959

Sorafenib tosylate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 2;8(18):29771-29784. [Abstract]

Sorafenib inhibits Pin1 biosynthesis and accumulation in Huh7 and HepG2 cells. Cells are treated with 5 or 10 μM Sorafenib for indicated times. Pin1 protein expression is determined by Western Blot.
Chem Cent J

Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD. [Abstract]

2017 Jan 3:11:1. PMID: 28101128
Am J Dig Dis (Madison)

2015;2(2):95-99.

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (156.98 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5698 mL

7.8489 mL

15.6978 mL

5 mM

0.3140 mL

1.5698 mL

3.1396 mL

10 mM

0.1570 mL

0.7849 mL

1.5698 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.92 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (307 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. [Content Brief]

[2]. Heim M, et al. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs. 2005;16(2):129-136. [Content Brief]

[3]. Gu FM, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3. World J Gastroenterol. 2011 Sep 14;17(34):3922-32. [Content Brief]

[4]. El-Ashmawy NE, et al. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med. 2016 Apr 16. [Content Brief]

[5]. Li M, et al. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. Br J Cancer. 2017;117(7):974-983. [Content Brief]

[6]. Jin W, et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Oncol Rep. 2017;37(1):273-280. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.5698 mL	7.8489 mL	15.6978 mL	39.2446 mL
	5 mM	0.3140 mL	1.5698 mL	3.1396 mL	7.8489 mL
	10 mM	0.1570 mL	0.7849 mL	1.5698 mL	3.9245 mL
	15 mM	0.1047 mL	0.5233 mL	1.0465 mL	2.6163 mL
	20 mM	0.0785 mL	0.3924 mL	0.7849 mL	1.9622 mL
	25 mM	0.0628 mL	0.3140 mL	0.6279 mL	1.5698 mL
	30 mM	0.0523 mL	0.2616 mL	0.5233 mL	1.3082 mL
	40 mM	0.0392 mL	0.1962 mL	0.3924 mL	0.9811 mL
	50 mM	0.0314 mL	0.1570 mL	0.3140 mL	0.7849 mL
	60 mM	0.0262 mL	0.1308 mL	0.2616 mL	0.6541 mL
	80 mM	0.0196 mL	0.0981 mL	0.1962 mL	0.4906 mL
	100 mM	0.0157 mL	0.0785 mL	0.1570 mL	0.3924 mL

Sorafenib tosylate

292 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Sorafenib tosylate

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Therapy Drug Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library